Listed by the USPTO as GRABER, JAMES J
Tech Center 1600 • Art Units: 1631 1633
This examiner grants 46% of resolved cases
GRABER, JAMES J is a USPTO patent examiner in Tech Center 1600 and art unit 1631. The profile covers 200 resolved cases, with an allowance rate of 46.5% and a median of 1389 days to allowance. Interview participation shows a lift of 57.6%, indicating a strong positive association with allowance in the recorded matters.
The leading companies are Duke University, St. Jude Children's Research Hospital Inc., and Editas Medicine Inc. The listed firms are POLSINELLI and DUKE UNIVERSITY, THOMAS | HORSTEMEYER, LLP, and AMSTER, ROTHSTEIN & EBENSTEIN LLP. For biotechnology and medical matters, practitioners may find it useful to pair a focused written response with an interview plan, then examine the specific claim features that preceded allowance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18890553 | Treatment of Mitochondrial Disease with Autologous Expanded Mesenchymal Stem Cell Therapy | Non-Final OA | Individual inventor |
| 18558859 | UNIVERSAL RETARGETING OF ONCOLYTIC HSV | Non-Final OA | Janssen Biotech, Inc. |
| 17430382 | MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY | Final Rejection | Editas Medicine, Inc. |
| 18289881 | 3D HUMAN DISTAL LUNG ORGANOIDS CONTAINING EPITHELIAL, IMMUNE AND MESENCHYMAL COMPONENTS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18832458 | RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS | Non-Final OA | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH |
| 18721743 | NON-HUMAN ANIMALS COMPRISING HUMANIZED ACE2 AND TMPRSS LOCI | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18568091 | METHODS FOR ENGINEERING AND USE OF CILIATED ORGANOIDS HAVING NATIVE-LIKE, APICAL-OUT POLARITY | Non-Final OA | Carnegie Mellon University |
| 18294033 | CULTURED ADIPOSE TISSUE | Non-Final OA | Trustees of Tufts College |
| 18248193 | PRODUCTION OF MEGAKARYOCYTES AND PLATELETS IN A CO-CULTURE SYSTEM | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17580219 | INCREASING GENOME STABILITY AND REPROGRAMMING EFFICIENCY OF INDUCED PLURIPOTENT STEM CELLS | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 17911018 | COMPOSITION FOR INDUCING APOPTOSIS OF CELLS HAVING GENOMIC SEQUENCE VARIATION AND METHOD FOR INDUCING APOPTOSIS OF CELLS BY USING COMPOSITION | Non-Final OA | UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) |
| 18840303 | MULTIPLEXED REPRESSION OF IMMUNOSUPPRESSIVE GENES | Non-Final OA | Yale University |
| 18707756 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | Non-Final OA | VERTEX PHARMACEUTICALS INCORPORATED |
| 18680912 | Methods of Producing Astrocytes or Promoting Astrocyte Development and Cell Culture Compositions Related Thereto | Non-Final OA | Emory University |
| 18547332 | Compositions For and Methods of Improving Gene Therapy | Non-Final OA | Duke University |
| 17637760 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | Final Rejection | DUKE UNIVERSITY |
| 17783040 | Method for Preparing CD7-Negative, CD3-Positive T Cells | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 17258533 | USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS | Final Rejection | St. Jude Children's Research Hospital |
| 18909327 | METHODS FOR TREATING NEUROLOGICAL DISEASES | Non-Final OA | Cytora Ltd. |
| 18854936 | ENZYME-FREE PROCESSES TO PRODUCE HYDROGELS | Non-Final OA | TISSUELABS PESQUISA E DESENVOLVIMENTO LTDA |
| 18567094 | COMPOSITIONS AND METHODS FOR ISLET CELL TRANSPLANTS | Non-Final OA | City of Hope |
| 18704322 | METHOD FOR PRODUCING ORGANISM, AND METHOD FOR PROMOTING DIFFERENTIATION OF HUMAN ADIPOSE-DERIVED STEM CELLS INTO VASCULAR ENDOTHELIAL CELLS | Final Rejection | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION |
| 18732209 | USE OF miR-34b IN REGULATING LIPID METABOLISM OF SHANDONG BLACK CATTLE | Non-Final OA | Qingdao Agricultural University |
| 18682797 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY TO REDUCE INSTANT BLOOD MEDIATED INFLAMMATORY REACTIONS | Non-Final OA | Sana Biotechnology, Inc. |
| 18715599 | METHODS FOR CELL CULTURING | Non-Final OA | Orbillion Bio, Inc. |
| 18686638 | METHOD FOR PRODUCING INNER EAR STRIA VASCULARIS MARGINAL CELLS, CHEMICAL AGENT ASSESSMENT METHOD, AND CELL CULTURE FOR ASSESSING CHEMICAL AGENT | Final Rejection | THE KITASATO INSTITUTE |
| 15780542 | SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE | Final Rejection | SPARK THERAPEUTICS, INC. |
| 18441393 | ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18439283 | ANIMAL MODEL OF CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR LEUKEMIA COMPLICATED BY CYTOKINE RELEASE SYNDROME (CRS), AND PREPARATION METHOD AND USE THEREOF | Non-Final OA | UNION HOSPITAL TONGJI MEDICAL COLLEGE HUST |
| 17745314 | MRNA FUNCTIONALIZATION METHOD | Non-Final OA | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.5% of resolved applications examined by James J Graber were allowed (200 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +57.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by James J Graber took 1,389 days on average from filing to allowance.
James J Graber examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
